Novartis announces the company’s financial results for the second quarter and first half of 2025.Novartis announces the company’s financial results for the second quarter and first half of 2025.
Showing 97 results
-
Coartem ®
Available in -
Comtan®
( entacapone )Neuroscience -
Cosentyx®
( secukinumab )Immunology and Dermatology -
Desferal®
Available in -
Diovan HCT® /Co-Diovan®
( valsartan, hydrochlorothiazide )Cardiovascular, Renal and Metabolism -
Diovan®
( valsartan )Cardiovascular, Renal and Metabolism -
Durezol®
( difluprednate )OphthalmologyAvailable in -
Egaten®
( triclabendazole )HepatologyAvailable in -
Entresto®
( sacubitril, valsartan )Cardiovascular, Renal and Metabolism